INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $9,157,197 | -50.8% | 1,644,021 | -49.4% | 0.42% | -44.6% |
Q1 2023 | $18,622,500 | +445.7% | 3,250,000 | 0.0% | 0.76% | +435.0% |
Q4 2022 | $3,412,500 | -60.8% | 3,250,000 | 0.0% | 0.14% | -64.2% |
Q3 2022 | $8,710,000 | -43.8% | 3,250,000 | 0.0% | 0.40% | -60.8% |
Q2 2022 | $15,503,000 | – | 3,250,000 | – | 1.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $10,852,000 | 4.54% |
CHI Advisors LLC | 892,057 | $6,084,000 | 2.02% |
Sofinnova Investments, Inc. | 2,028,308 | $13,833,000 | 0.81% |
MPM BioImpact LLC | 302,615 | $2,064,000 | 0.38% |
NEA Management Company, LLC | 2,444,379 | $16,671,000 | 0.34% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $15,991,000 | 0.34% |
Rock Springs Capital Management LP | 868,466 | $5,923,000 | 0.14% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,013,216 | $6,910,000 | 0.13% |
Orbimed Advisors | 526,600 | $3,591,000 | 0.05% |
Overbrook Management Corp | 16,726 | $114,000 | 0.02% |